Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female

Summary

This is a multi-centre, randomised, double blind, placebo-controlled study on female participants with diagnosis of high-risk human papillomavirus (HR-HPV) infection to evaluate the clearance capacity of AHCC®.

Timeline

Start

2020-10-26

Primary completion

2024-06-30

Completion

2024-12-31

Drugs

Indications